Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
…, A Pandey, P Ranganadin, R Gumashta, M Multani… - The Lancet, 2021 - thelancet.com
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[PDF][PDF] Clinical and biochemical profile of Indians with type 2 diabetes mellitus: A problem lurking for India
Background: To define the profile of type 2 diabetes mellitus population from the Gwalior
region of Madhya Pradesh, as the previous published data shows a pattern and profile …
region of Madhya Pradesh, as the previous published data shows a pattern and profile …
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
…, A Pandey, P Ranganadin, R Gumashta, M Multani… - 2021 - pesquisa.bvsalud.org
… Raches Ella MBBS, MS; Siddharth Reddy MSc; William Blackwelder PhD; Varsha Potdar
PhD; Pragya Yadav PhD; Vamshi Sarangi BSc; Vinay Kumar Aileni PhD; Suman Kanungo …
PhD; Pragya Yadav PhD; Vamshi Sarangi BSc; Vinay Kumar Aileni PhD; Suman Kanungo …
[PDF][PDF] Is existing cervical cancer screening proven productive in developing nations: Time to move from the laboratory to community?
Dear Editor, Cervical cancer is the leading cancer among Indian women with the estimated
age standardized incidence and mortality rates around 2008 of 27 and 15/100,000 women …
age standardized incidence and mortality rates around 2008 of 27 and 15/100,000 women …
Acute myocardial infarction in a 28-year-old man from embolized left atrial myxoma
P Rastogi, G Dhanuka, MK Multani… - Nigerian Journal of …, 2014 - journals.lww.com
Atrial myxoma has been reported as source of coronary emboli, a rare complication, causing
acute myocardial infarction (MI). We report case of a 28-year-old male, who presented with …
acute myocardial infarction (MI). We report case of a 28-year-old male, who presented with …
Pulmonary arterial hypertension in pregnancy
MK Multani, P Uttarwar - Nigerian Journal of Cardiology, 2015 - journals.lww.com
Pulmonary hypertension (PH) in pregnancy is associated with high morbidity and mortality
of mother and baby. Therefore, pulmonary hypertension (PH) is regarded as a …
of mother and baby. Therefore, pulmonary hypertension (PH) is regarded as a …
Abdominal aortic thrombosis in a young male patient living with human immuno deficiency virus/acquired immune deficiency syndrome
Abdominal aortic thrombosis in a young male patient living w... : Nigerian Journal of
Cardiology Abdominal aortic thrombosis in a young male patient living with human immuno …
Cardiology Abdominal aortic thrombosis in a young male patient living with human immuno …
A Case of Acquired Ventricular Septal Defect Complicating Silent Myocardial Infarction: An Unusual Presentation
Ventricular septal defect (VSD) is a rare, but serious complication of acute myocardial infarction
requiring early surgical intervention. We report a case of a 75-year-old man, who had a …
requiring early surgical intervention. We report a case of a 75-year-old man, who had a …
A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105
…, JW Oliver, D Trone, K McArthur, R Patel, PS Multani… - Cancer discovery, 2019 - AACR
Although KIF5B–RET is the most common RET fusion in NSCLCs, RET inhibition with RXDX-105
resulted in responses only in non– KIF5B–RET -containing cancers. Novel approaches …
resulted in responses only in non– KIF5B–RET -containing cancers. Novel approaches …
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and …
…, D Luo, E Chow-Maneval, Z Hornby, PS Multani… - Cancer discovery, 2017 - AACR
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …